Identification and Characterization of a 100-kD Ligand for CD6 on Human Thymic Epithelial Cells

By Dhavalkumar D. Patel,* Siow-Fong Wee,† Leona P. Whichard,† Michael A. Bowen,‡ John M. Pesando,§ Alejandro Aruffo,‡ and Barton F. Haynes*

From the *Division of Rheumatology, Allergy and Clinical Immunology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710; †Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98195; and §Oncomembrane, Seattle, Washington 98102

Summary

CD6 is a 130-kD glycoprotein expressed on the surface of thymocytes and peripheral blood T cells that is involved in TCR-mediated T cell activation. In thymus, CD6 mediates interactions between thymocytes and thymic epithelial (TE) cells. In indirect immunofluorescence assays, a recombinant CD6-immunoglobulin fusion protein (CD6-Rg) bound to cultured human TE cells and to thymic fibroblasts. CD6-Rg binding to TF and TE cells was trypsin sensitive, and 54 ± 4% of binding was divalent cation dependent. By screening the blind panel of 479 monoclonal antibodies (mAbs) from the 5th International Workshop on Human Leukocyte Differentiation Antigens for expression on human TE cells and for the ability to block CD6-Rg binding to TE cells, we found one mAb (J4-81) that significantly inhibited the binding of CD6-Rg to TE cells (60 ± 7% inhibition). A second mAb to the surface antigen identified by mAb J4-81, J3-119, enhanced the binding of CD6-Rg to TE cells by 48 ± 5%. Using covalent cross-linking and trypsin digestion, we found that mAb J4-81 and CD6-Rg both bound to the same 100-kD glycoprotein (CD6L100) on the surface of TE cells. These data demonstrate that a 100-kD glycoprotein on TE cells detected by mAb J4-81 is a ligand for CD6.
with 0.2% trypsin in PBS containing 1 mM EDTA for 30 min.

**Detection of Cell Surface Antigens.** Cells, suspended in either PBS or DMEM (with or without 10 mM EDTA) containing 2% BSA and 0.1% NaN₃, were incubated with a recombinant CD6-Ig fusion protein (CD6-Rg) (27), CD5-Rg (28), or human IgG (Sigma Chemical Co., St. Louis, MO) (100 μg/ml) for 30 min at 4°C and washed with PBS containing 2% BSA and 0.1% NaN₃. Fluorescein-conjugated goat anti-human IgG1 (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) was used as a secondary reagent. Cells were analyzed on a FACStar™ flow cytometer (Becton Dickinson & Co., Mountain View, CA). To determine trypsin sensitivity of fusion protein interactions, cells were incubated with 0.2% trypsin in PBS containing 1 mM EDTA for 30 min at 37°C and washed before reactivity with fusion proteins.

**Screening of mAbs for Inhibition of CD6-Rg Binding to TE Cells.** mAbs from the blind panel of the HLDA-V and a panel of anti-integrin mAbs were screened for reactivity to the surface of TE cells (29). Of the 154 mAbs that reacted with TE cells, 126 were used in this assay. TE cells (10⁴) were incubated with ascites or purified mAb (1:100) for 15 min at 4°C. Either CD5-Rg or CD6-Rg (5 μg) were added and allowed to react for 2 h at 4°C, washed, and, labeled with a fluorescein-conjugated antiserum specific for the Fc portion of human IgG (Sigma Chemical Co.). To account for any cross-reactivity of fluorescein-conjugated anti-human IgG with murine Ig, binding was determined as the difference in fluorescence (∆FL) between samples containing CD6-Rg and CD5-Rg.

**Immunoprecipitation and Protein Cross-linking Conditions.** TE cells, surface labeled with ¹²⁵I as described (30), were incubated with mAbs (1:100 ascites), purified Ig (200 μg/ml), or Ig fusion proteins (200 μg/ml) for 2 h in DME/5% FBS. After washing with cold PBS, bound Iggs were cross-linked to cell surface proteins with 1 mM 3,3' dithiobis(sulfo-succinimidyl propionate) (DTSSP) (Pierce Chemical Co., Rockford, IL) in PBS for 60 min at 4°C. After addition of 20 mM Tris-HCl (pH 8.0), the cells were washed with cold PBS. Cells were lysed in PBS containing 1% NP-40, 1 mM PMSF, 0.1 mM Na₃P·Tosyl-L-lysine chloromethyl ketone (TLCK) and 0.1% NaN₃. Ig complexes were purified with protein A-Sepharose beads (Sigma Chemical Co.). Before SDS-PAGE, protein complexes were solubilized with SDS loading buffer (2% SDS, 10 mM Tris-HCl, pH 7.4, 20% glycerol, bromphenol blue) containing 2% 2-ME. To confirm identity of proteins, purified protein complexes were treated with 0.2% trypsin in 1 mM EDTA for 30 min at 25°C (31) before solubilization and cross-linker cleavage. After SDS-PAGE, the gels were fixed, dried, and exposed to autoradiography film.

**Results**

**CD6-Rg Binding to Cells of the Thymic Microenvironment.** The ability of CD6-Rg fusion protein to bind to TE cells, thymic fibroblasts, and thymocytes was determined by indirect IF and flow cytometry. CD6-Rg bound to the surface of TE cells as well as to thymic fibroblasts, but not to thymocytes (Fig. 1A). Binding of CD6-Rg to TE cells was trypsin sensitive and partially dependent upon divalent cations (Fig. 1B). CD6-Rg bound well to TE cells in a buffer containing DME and 5% fetal bovine serum, but in the presence of 10 mM EDTA, binding of CD6-Rg to TE cells was inhibited by 54 ± 4% (n = 5, p < 0.001, Fig. 1B).

**Antibody-mediated Inhibition of CD6-Rg Binding to TE Cells.** To begin to identify the CD6 ligand(s), a panel of 479 mAbs from HLDA-V was screened for reactivity to the surface of TE cells by indirect IF and flow cytometry. Of the 154 mAbs that reacted with the surface of TE cells (29), 126 mAbs were used in assays to inhibit the binding of CD6-Rg to TE cells. Of the 122 mAbs that did not react with the secondary antiserum, only one (J4-81) inhibited the binding of CD6-Rg to TE cells. mAb J4-81 inhibited the binding of CD6-Rg to TE cells by 60 ± 7% (n = 10, p < 0.001) and to the breast cell line HBL-100 by 40 ± 3% (n = 3, p < 0.02) (Table 1), which has also been shown to bind CD6-
Table 1. mAb Inhibition of CD6-Rg Binding to TE and HBL-100 Cells

| Cell Type | mAb | Δ FL† | Percent binding‡ | Percent inhibition§ |
|-----------|-----|------|------------------|--------------------|
| TE cells  | P3  | 52   | 100              | 0                  |
| CD9       | 60  | 115  | -15              | -15                |
| CD24      | 48  | 92   | 8                |                    |
| CD40      | 48  | 92   | 8                |                    |
| CD46      | 57  | 110  | -10              | -10                |
| CD51      | 46  | 88   | 12               |                    |
| CD54      | 44  | 85   | 15               |                    |
| CD58      | 45  | 87   | 13               |                    |
| CD59      | 52  | 100  | 0                |                    |
| CD63      | 53  | 102  | -2               | -2                 |
| CD66      | 56  | 108  | -8               | -8                 |
| J4-81     | 21  | 40   | 60               |                    |
| HBL-100   | P3  | 58   | 100              | 0                  |
| J4-81     | 34  | 59   | 41               |                    |

† ΔFL = Fluorescence (CD6-Rg) - fluorescence (CD5-Rg). Shown is the binding of CD6-Rg compared with control (CD5-Rg) in the presence of selected mAbs that bind well to the surface of TE cells.
‡ f = 100 x [ΔFL(experimental mAb) - ΔFL(P3)]/ΔFL(P3).
§ s = 100 x [ΔFL(P3) - ΔFL(experimental mAb)]/ΔFL(P3).

Rg (27). In flow cytometry assays, both TE and HBL-100 cells reacted strongly with mAb J4-81 (data not shown).

mAb J3-119, reported to react with a second epitope on the molecule detected by J4-81 (25), enhanced the binding of CD6-Rg to TE cells (Fig. 2) by 48 ± 5% (n = 6, p < 0.005), and to HBL-100 cells by 45 ± 11% (n = 3, p < 0.1). To confirm that mAb J3-119 recognized the same protein as mAb J4-81, the ability of mAb J3-119 to block the binding of biotinylated J4-81 to TE cells was tested. Whereas mAb A3D8 to CD44 (which binds to the surface of TE cells; 29) had no effect on J4-81 binding, both J4-81 and J3-119 mAbs inhibited the binding of biotinylated J4-81 (99 and 82%, respectively; data not shown).

mAb J4-81 and CD6-Rg Bind 100-kD TE Cell Proteins that Are Identical. To identify the TE cell surface protein(s) that bound to CD6-Rg, we devised a strategy whereby CD6-Rg interactions with CD6 ligand(s) on surface 125I-labeled TE cells were stabilized with DTSSP, and CD6-Rg-containing complexes were purified using protein A-Sepharose beads. Using this strategy, CD6-Rg specifically reacted with a 100-kD TE cell surface protein (Fig. 3) termed CD6L-100. mAb J4-81 cross-linked to 125I-labeled TE cells also yielded a 100-kD protein that migrated with the 100-kD protein recognized by CD6-Rg (Fig. 3). Trypsin digestion studies showed that the 100-kD protein identified by J4-81 had an identical trypsin digestion pattern to the protein identified by CD6-Rg (Fig. 3), indicating that both proteins were identical. CD6L-100 was determined to be a glycoprotein as mAb J4-81 immunoprecipitated CD6L-100 from extracts of TE cells metabolically labeled with [3H]glucosamine (data not shown).

The 100-kD CD6 Ligand is a Divalent Cation-independent Ligand for CD6. CD6-Rg was able to immunoprecipitate CD6L-100 in the presence and absence of divalent cations, suggesting that CD6L-100 may be a divalent cation-independent CD6 ligand. Further, J4-81 only partially inhibited the binding of CD6-Rg to TE cells in the presence of divalent cations. Thus, there may be more than one ligand for CD6. mAb J4-81 almost completely inhibited (80 ± 10% inhibition, p < 0.1) CD6-Rg binding to TE cells in the presence of EDTA (Fig. 2), confirming that it is primarily involved in divalent cation-independent CD6-CD6 ligand interactions. In contrast, mAb J3-119 enhanced CD6-Rg binding by 47 ± 7% (p < 0.1) in the absence of divalent cations (Fig. 2).

Tissue Distribution of mAb J4-81 Reactivity. The tissue distribution of CD6L-100 was examined on frozen sections of a variety of human tissues by indirect IF (Table 2). The reactivity of mAb J4-81 with human tissues was broad. Whereas CD6 was expressed on thymocytes in postnatal human thymus,
CD6L-100 was expressed on cortical and medullary TE cells and Hassall's bodies (Fig. 4). In tissues other than thymus, J4-81 reacted with epidermal keratinocytes, gut epithelium, breast epithelium, pancreatic acinar cells, pancreatic islet cells, hepatocytes, renal tubular epithelium, neurons of the cerebral cortex, and fibroblasts.

**Discussion**

In this study, we have shown that human thymic epithelial cells and fibroblasts express a ligand for CD6, termed CD6L-100. We have found two mAbs, J4-81 and J3-119, that bind to CD6L-100 and alter the binding of CD6-Rg to TE cells. Cross-linked immunoprecipitation experiments and trypsin digestion revealed that the 100-kD molecule bound by CD6-Rg and by J4-81 were identical.

Whereas the role of CD6 as an accessory molecule in T cell activation is well established (12–15), its role in T cell development is not clear. Vollger et al. (3) initially suggested that CD6 may be an adhesion molecule involved in TE-thymocyte binding as the anti-CD6 mAbs T12 and 12.1 were able to partially block the binding of human thymocytes to cultured human TE cells. Identification of the ligand(s) for CD6 may provide a better understanding of the role of CD6 in T cell differentiation and activation (16, 20, 27).

Partial inhibition of CD6-Rg binding to TE cells and thymic fibroblasts by EDTA suggested that there may be more than one ligand for CD6, or that the CD6 ligand may have different states of activation depending on divalent cations. Interestingly, a 31-kD surface molecule was frequently immunoprecipitated along with CD6L-100 from B cells by mAbs J4-81 and J3-119 (25). Whereas we have clearly established that CD6L-100 is a divalent cation-independent ligand for CD6, other ligands for CD6 may exist and CD6L-100 may complex with other proteins that regulate CD6 binding (Wee, S. F., D. D. Patel, B. F. Haynes, and A. Aruffo, unpublished observations).

CD6L-100 has a broad tissue distribution, with expression on a variety of cell types in normal tissues as defined by mAb J4-81 (Fig. 4, Table 2). mAb J4-81 was also tested in the blind panel of HLDA-V, and was shown to react with the surface of the following human cell types: CD34 hi and CD34 low bone marrow cells, resting and TNF-activated human umbilical vein endothelial cells, dermal endothelial cells, activated peripheral blood B and T cells, a variety of B cell and T cell lymphomas, monocytes, myeloid leukemias, thymic epithelial cells, epidermal keratinocytes, skin and lung fibroblasts, and a variety of stromal cell carcinomas (26). The broad distribution of CD6L-100 is consistent with the previous report that CD6-Rg binds to a number of murine lymphoid tissues and transformed human cell lines (27). The expression of CD6L-100 in normal noninflamed nonlymphoid tissues combined with the accessory role of CD6 in T cell activation implies that CD6-CD6L interactions may be functional in the earliest stages of T cell activation, before upregulation of MHC and adhesion molecules by T cell–liberated cytokines. CD6L-100 expression did not change with INF-γ activation of TE cells (29) or TNF-α activation of endothelial

**Table 2. Reactivity of mAb J4-81 in Sections of Normal Human Tissues**

| Tissue (number tested) | J4-81 Reactivity |
|------------------------|------------------|
| Thymus (5)             | Hassall's bodies, epithelium, fibroblasts |
| Spleen (2)             | Scattered mononuclear cells |
| Lymph node (1)         | Scattered mononuclear cells |
| Tonsil (2)             | Pharyngeal epithelium, lymphocytes |
| Appendix (1)           | Fibroblasts, lymphoid cells, epithelium |
| Colon (2)              | Fibroblasts, epithelium |
| Esophagus (2)          | Basal epithelium |
| Breast (2)             | Epithelium, fibroblasts |
| Liver (2)              | Hepatocytes, Kupfer cells, fibroblasts |
| Pancreas (2)           | Acinar and islet cells |
| Kidney (2)             | Fibroblasts, subset of tubules, Bowman's capsule |
| Skin (2)               | Perivascular fibroblasts, epithelium |
| Brain (2)              | Neurons |

The cell types reacting with mAb J4-81 in each of the tissue types are listed.
Figure 4. Expression of CD6L-100 in postnatal human thymus. Shown are photomicrographs (representative of experiments on five thymuses) of frozen sections of 2-mo-old human thymus stained by indirect IF with mAb J4-81. (A) A section of thymus cortex and B shows a section of thymus medulla with Hassall's bodies (HB). The thymic capsule is indicated by dashed lines in A. Thymic epithelial cells (arrow), in both the cortex and in and around HB in medulla, reacted with mAb J4-81. Thymocytes did not react with mAb J4-81. An identical pattern was seen using mAb J3-119 (not shown). ×400.

CD6-CD6L interactions may also be important in the nervous system as neurons of the cerebral cortex express both CD6 (10) and CD6L-100.

Ostorio et al. (16) have suggested that the ability of CD6 to enhance antigen-TCR signaling could be physiologically significant especially in cases of low levels of antigen or in antigen interaction with TCRs of low avidity for the antigen. This theory fits well with the recent findings that whereas CD6+ peripheral T cells have normal proliferative responses to T cell mitogens (PHA, anti-CD2 mAb, and immobilized anti-CD3 mAb) and soluble antigen (tetanus toxin) plus APC, CD6+ T cells are less alloreactive than unfractionated PB T cells (19). Further, CD6 mAb UMCD6 inhibited the response of cloned T cells in autologous MLRs (20). Thus, inhibition of CD6-CD6 ligand interactions by depletion of CD6+ peripheral blood T cells or therapeutic use of anti-CD6 mAbs, soluble CD6, anti-CD6 ligand mAbs, or soluble CD6 ligands may decrease autoreactivity in specific autoimmune disease states.

Finally, we have defined two different epitopes of the CD6L-100 molecule using mAbs J4-81 and J3-119. mAb J4-81 inhibited CD6-Rg binding to TE cells whereas J3-119 enhanced CD6-Rg binding. These two epitopes may overlap as J3-119 inhibited the binding of J4-81 to TE cells. Alternatively, mAb J3-119 inhibition of J4-81 binding could also have been due to a change in the conformation of CD6L-100 induced by J3-119 binding. Thus, the enhanced binding of CD6-Rg in the presence of mAb J3-119 suggested that mAb J3-119 may either induce or stabilize the active conformation of CD6L-100. Similarly, mAb J4-81 may either be directed to the CD6 binding site or stabilize the inactive conformation of CD6L-100. Nucleotide sequence analysis of the gene encoding CD6L-100 and functional studies using mAbs J4-81 and J3-119 in assays of cell interactions, T cell autoreactivity, and T cell responses to specific antigen should help further define the roles of CD6-CD6 ligand interactions in T cell development and T cell effector function.

We thank Brett Modrell for CD6-Rg preparations, and Kim McClammy for secretarial assistance.

This work was supported by National Institutes of Health grant CA28936 to B. F. Haynes, Department of Energy grant DE-F006-86-ER60409 to A. Aruffo, and the Bristol-Myers Squibb Pharmaceutical Research Institute.

Address correspondence to Dr. D. D. Patel, Box 3258, CARL Building, Duke University Medical Center, Durham, NC 27710. S.-F. Wee's present address is Immunex Corp., Seattle, WA 98101.

Received for publication 6 October 1994 and in revised form 16 December 1994.

References

1. Patel, D.D., and B.F. Haynes. 1993. Cell adhesion molecules involved in intrathymic T cell development. Semin. Immunol. 5:283-292.

2. Pawlowski, T.J., and U.D. Staerz. 1994. Thymic education—T cells do it for themselves. Immunol. Today. 15:205-209.

3. Vollger, L.W., D.T. Tuck, T.A. Springer, B.F. Haynes, and K.H.
Singer. 1987. Thymocyte binding to human thymic epithelial cells is inhibited by monoclonal antibodies to CD-2 and LFA-3 antigens. J. Immunol. 139:358–363.

4. Singer, K.H., S.M. Denning, L.P. Whichard, and B.F. Haynes. 1990. Thymocyte LFA-1 and thymic epithelial cell ICAM-1 molecules mediate binding of activated human thymocytes to thymic epithelial cells. J. Immunol. 144:2931–2939.

5. Giunta, M., A. Favre, D. Ramarli, C.E. Grossi, and G. Corte. 1991. A novel integrin involved in thymocyte–thymic epithelial cell interactions. J. Exp. Med. 173:1537–1548.

6. Imhof, B.A., P. Ruiz, B. Hesse, R. Palacios, and D. Dunon. 1991. EA-1, a novel adhesion molecule involved in the homing of progenitor T lymphocytes to the thymus. J. Cell. Biol. 114:1069–1078.

7. Utsumi, K., M. Sawada, S. Narumiya, J. Nagamine, T. Sakata, S. Iwagami, Y. Kita, H. Teraoka, H. Hirano, M. Ogata, et al. 1991. Adhesion of immature thymocytes to thymic stromal cells through fibronectin molecules and its significance for the induction of thymocyte differentiation. Proc. Natl. Acad. Sci. USA. 88:5685–5689.

8. Reinherz, E.L., S. Meuer, K.A. Fitzgerald, R.E. Hussey, H. Levine, and S.F. Schlossman. 1982. Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex. Cell. 30:735–743.

9. Kamoun, M., M.E. Kadin, P.J. Martin, J. Nettleton, and J. Hansen. 1981. A novel human T cell antigen preferentially expressed on mature T cells and shared by both well and poorly differentiated B cell leukemias and lymphomas. J. Immunol. 127:987–991.

10. Mayer, B., I. Funke, B. Seed, G. Riethmuller, and E. Weiss. 1990. Expression of the CD6 T lymphocyte differentiation antigen in normal human brain. J. Neuroimmunol. 29:193–202.

11. Aruffo, A., M.B. Melnick, P.S. Linsley, and B. Seed. 1991. The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins. J. Exp. Med. 174:949–952.

12. Gangemi, R.M.R., J.A. Swack, D.M. Gaviria, and P.L. Romain. 1989. Anti-T11, an anti-CD6 monoclonal antibody, can activate human T lymphocytes. J. Immunol. 143:2439–2447.

13. Morimoto, C., C.E. Rudd, N.L. Letvin, M. Hagan, and S.F. Schlossman. 1988. 2H1—a novel antigen involved in T lymphocyte triggering. J. Immunol. 140:2165–2170.

14. Swack, J.A., R.M.R. Gangemi, C.E. Rudd, C. Morimoto, S.F. Schlossman, and P.L. Romain. 1989. Structural characterization of CD6: properties of two distinct epitopes involved in T cell activation. Mol. Immunol. 26:1037–1049.

15. Ledbetter, J.A., N.A. Norris, A. Grossman, L.S. Grosmaire, C.H. June, F.M. Uckun, W.L. Cosand, and P.S. Rabinowitch. 1989. Enhanced transmembrane signalling activity of monoclonal antibody heteroconjugates suggests molecular interactions between receptors on the T cell surface. Mol. Immunol. 26:137–145.

16. Osorio, L.M., C.A. Garcia, M. Jondal, and S.C. Chow. 1994. The anti-CD6 mAb, IOR-T1, defined a new epitope on the human CD6 molecule that induces greater responsiveness in T cell receptor/CD3-mediated T cell proliferation. Cell. Immunol. 154:123–133.

17. Wee, S.F., G.L. Schievien, J.M. Kirihara, T.T. Tsu, J.A. Ledbetter, and A. Aruffo. 1993. Tyrosine phosphorylation of CD6 by stimulation of CD3: augmentation by the CD4 and CD2 coreceptors. J. Exp. Med. 177:219–223.

18. Soiffer, R.J., C. Murray, P. Mauch, K.C. Anderson, A.S. Freedman, S.N. Rabinowe, T. Takvorian, M.J. Robertson, N. Spector, R. Gonin, et al. 1992. Prevention of graft-versus-host disease by selective depletion of CD6 positive T lymphocytes from donor marrow. J. Clin. Oncol. 10:1191–1200.

19. Rasmussen, R.A., S.L. Counts, J.F. Daley, and S.F. Schlossman. 1994. Isolation and characterization of CD6- T cells from peripheral blood. J. Immunol. 152:527–536.

20. Singer, N.G., B.C. Richardson, D. Powers, F. Hooper, C.M. Borr, F. Lalios, J. Sanders, and D.A. Fox. 1994. Autoreactivity of human cloned T lymphocytes: an essential role for the CD6 glycoprotein. Clin. Res. 42:232a.

21. Singer, K.H., E.A. Harden, A.L. Robertson, D.F. Lobach, and B.F. Haynes. 1985. In vitro growth and phenotypic characterization of mesodermal-derived and epithelial components of normal and abnormal human thymus. Hum. Immunol. 13:161–176.

22. Singer, K.H., R.M. Scearce, D.T. Tuck, L.P. Whichard, S.M. Denning, and B.F. Haynes. 1989. Removal of fibroblasts from human epithelial cell cultures with the use of a complement fixing monoclonal antibody reactive with human fibroblasts and monocytes/macrophages. J. Invest. Dermatol. 92:166–170.

23. Denning, S.M., D.T. Tuck, L.W. Vollger, T.A. Springer, K.H. Singer, and B.F. Haynes. 1987. Monoclonal antibodies to CD2 and LFA-3 inhibit human thymic epithelial cell-dependent mature thymocyte activation. J. Immunol. 139:2573–2578.

24. Telen, M.J., G.S. Eisenbarth, and B.F. Haynes. 1983. Human erythrocyte antigens: Regulation of expression of a novel erythrocyte surface antigen by the inhibitor Lutheran In(Lu) gene. J. Clin. Invest. 71:1878–1886.

25. Pesando, J.M., P. Hoffman, and M. Abed. 1986. Antibody-induced antigenic modulation is antigen dependent: characterization of 22 proteins on a malignant human B cell line. J. Immunol. 137:3689–3695.

26. Shaw, S. 1995. Concepts of cross-lineage (blind panel) analysis of expression of differentiation antigens. In Leukocyte Typing V. S. Schlossman, L. Boumsell, W. Gilks, J. Harlan, T. Kishimoto, C. Morimoto, J. Ritz, S. Shaw, R. Silverstein, T. Springer, et al., editors, Oxford University Press, Oxford, UK. In press.

27. Wee, S.F., W.C. Wang, A.G. Farr, A.J. Nelson, D.D. Patel, B.F. Haynes, P.S. Linsley, and A. Aruffo. 1994. Characterization of a CD6 ligand(s) expressed on human- and murine-derived cell lines and murine lymphoid tissues. Cell. Immunol. 158:353–364.

28. Aruffo, A., S.B. Kanner, D. Sgroi, J.A. Ledbetter, and I. Stamnenkovic. 1992. CD22-mediated stimulation of T cells regulates T-cell receptor/CD3-induced signaling. Proc. Natl. Acad. Sci. USA. 89:10242–10246.

29. Patel, D.D., L.P. Whichard, G. Radcliff, S.M. Denning, and B.F. Haynes. 1995. Characterization of human thymic epithelial cell surface antigens: phenotypic similarity of thymic epithelial cells to epidermal keratocyes. J. Clin. Immunol. In press.

30. Jones, P.P. 1980. Analysis of radiolabeled lymphocyte proteins by one- and two-dimensional polyacrylamide gel electrophoresis. In Selected Methods in Cellular Immunology. B.B. Mishell and S.M. Shiigi, editors. W.H. Freeman and Company, New York. 398–440.

31. Patel, D.D., D.J. Pickup, and W.K. Joklic. 1986. Isolation of cowpox virus A-type inclusions and characterization of their Listeria monocytogenes. Virology. 149:174–189.

32. Haynes, B.F., L.L. Hensley, and B.V. Jegasothy. 1982. Differentiation in skin and blood malignant cells in cutaneous T cell lymphoma. J. Invest. Dermatol. 768:323–326.